Yamamoto, N., Goto, K., Nishio, M., Chikamori, K., Hida, T., Maemondo, M., . . . Tamura, T. (2016). Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Int J Clin Oncol.
Citação norma ChicagoYamamoto, Noboru, et al. "Final Overall Survival in JO22903, a Phase II, Open-label Study of First-line Erlotinib for Japanese Patients With EGFR Mutation-positive Non-small-cell Lung Cancer." Int J Clin Oncol 2016.
Citação norma MLAYamamoto, Noboru, et al. "Final Overall Survival in JO22903, a Phase II, Open-label Study of First-line Erlotinib for Japanese Patients With EGFR Mutation-positive Non-small-cell Lung Cancer." Int J Clin Oncol 2016.